Babur Bhatti, MD
Psychiatry · Jacksonville, FLNPI 1245525781
Payments from drug & device makers
Across 356 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$750
- Alkermes, Inc.$609
- Indivior Inc.$367
- plus $1K from 20 others
What the payments were for
- Food & beverage$6,84497%
- Education$1793%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 76 | $1,533 |
| Otsuka America Pharmaceutical, Inc. | 76 | $1,477 |
| Teva Pharmaceuticals USA, Inc. | 49 | $1,086 |
| AbbVie(2 entities) | 51 | $750 |
| Alkermes, Inc. | 25 | $609 |
| Indivior Inc. | 18 | $367 |
| E.r. Squibb & Sons, L.L.C. | 8 | $207 |
| Neurocrine Biosciences, Inc. | 10 | $194 |
| Vanda Pharmaceuticals Inc. | 7 | $152 |
| Lundbeck LLC | 6 | $108 |
| Almatica Pharma LLC | 6 | $92 |
| Noven Therapeutics, LLC | 3 | $71 |
| Braeburn Inc. | 3 | $69 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| CSL Behring | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Neuronetics, Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Neos Therapeutics, LP | 1 | $13 |
| Tris Pharma Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$469
- INVEGA SUSTENNA$137
- VRAYLAR$122
- ABILIFY MAINTENA$115
- REXULTI$109
How this compares
$7,023 in reported general payments places this provider in the 80th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 134 | $157,907 |
| IngrezzaValbenazine Tosylate | 13 | $103,478 |
| Invega SustennaPaliperidone Palmitate | 19 | $47,720 |
| VraylarCariprazine Hcl | 20 | $27,702 |
| RexultiBrexpiprazole | 12 | $20,448 |
| Paliperidone ErPaliperidone | 37 | $9,574 |
| Aripiprazole | 148 | $9,228 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 55 | $7,622 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,738 |
| Trazodone Hcl | 368 | $4,566 |
| Quetiapine Fumarate | 225 | $3,941 |
| Duloxetine Hcl | 211 | $3,754 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 56 | $3,730 |
| Lurasidone Hcl | 26 | $3,480 |
| Atomoxetine Hcl | 28 | $2,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Sustenna | $1,533 | $205,626153 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $194 | $103,47813 claims |
| AbbVieVraylar | $750 | $27,70220 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,477 | $20,44812 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $20 | $4,73812 claims |
| Almatica Pharma LLCSertraline Hcl | $92 | $1,199187 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Jacksonville
- John JoyceJacksonville$13.6M
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.